首页> 外文期刊>Bone marrow transplantation >Large scale purification of human blood CD34+ cells from cryopreserved peripheral blood stem cells, using a nylon-fiber syringe system and immunomagnetic microspheres.
【24h】

Large scale purification of human blood CD34+ cells from cryopreserved peripheral blood stem cells, using a nylon-fiber syringe system and immunomagnetic microspheres.

机译:使用尼龙纤维注射器系统和免疫磁性微球,从冷冻保存的外周血干细胞中大规模纯化人血CD34 +细胞。

获取原文
获取原文并翻译 | 示例
       

摘要

Isolation of large numbers of human peripheral blood CD34+ cells could lead to therapeutic applications, including purging of malignant cells from blood cell transplantations, purging of T cells from allogeneic bone marrow, and even blood cell transplantation. This procedure has limitations if there are not sufficient numbers of progenitor cells in the leukapheresis concentrates available for selection after detection of tumor cells in apheresis products. Use of frozen/thawed peripheral blood mononuclear cell (PBMC) samples would make feasible pooling of two or even more stem cell harvests collected at different time points and the total number of CD34+ progenitor cells available would increase. We established an efficient method for purification of CD34+ cells from cryopreserved apheresis products, using a nylon-fiber syringe system and immunomagnetic microspheres. We compared purity, recovery rate and clonogenicity of CD34+ cells purified from fresh (n = 22) and cryopreserved apheresis products (n = 14), using a nylon-fiber syringe system and immunomagnetic microspheres. The purity of CD34+ cells from cryopreserved products was less than that from fresh products (85.9 +/- 14.4% vs 94.6 +/- 10.0%), but the recovery rate of CD34+ cells and colony-forming cells was comparable between fresh and cryopreserved products. One patient underwent grafting with peripheral blood CD34+ cells selected after freezing, with good success. Therefore, these cells are capable of rapidly reconstituting hematopoiesis after high-dose chemotherapy. Bone Marrow Transplantation (2000) 26, 787-793.
机译:分离大量人类外周血CD34 +细胞可导致治疗应用,包括从血细胞移植中清除恶性细胞,从同种异体骨髓中清除T细胞,甚至是血细胞移植。如果在单采血液分离物中检测到肿瘤细胞后,白细胞分离浓缩液中没有足够数量的祖细胞可供选择,则该程序有局限性。使用冷冻/解冻的外周血单个核细胞(PBMC)样品将使在不同时间点收集的两个或更多干细胞收集物的合并可行,并且可用的CD34 +祖细胞总数将增加。我们建立了一种有效的方法,使用尼龙纤维注射器系统和免疫磁性微球从冷冻的单采血液分离术产品中纯化CD34 +细胞。我们比较了使用尼龙纤维注射器系统和免疫磁性微球从新鲜(n = 22)和冷冻保存的单采血液分离产品(n = 14)中纯化的CD34 +细胞的纯度,回收率和克隆形成性。冷冻保存产品中CD34 +细胞的纯度低于新鲜产品(85.9 +/- 14.4%vs 94.6 +/- 10.0%),但是新鲜和冷冻产品中CD34 +细胞和集落形成细胞的回收率相当。一名患者接受冷冻后选择的外周血CD34 +细胞移植,取得了良好的成功。因此,这些细胞在大剂量化疗后能够快速重建造血功能。骨髓移植(2000)26,787-793。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号